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Abstract 
Aims Mitochondrial haplogroups are known to influence individual predisposition to a 
wide spectrum of metabolic and degenerative diseases, including ischemic 
cardiovascular diseases. We have examined the influence of the mitochondrial DNA 
(mtDNA) background on the development of human end-stage heart failure (HF) in 
patients undergoing heart transplantation. The influence of mtDNA haplogroups on the 
incidence of transplant-related complications, mainly cardiac allograft vasculopathy 
(CAV), and on post-transplant survival was also studied. 
Methods and Results The most common mitochondrial haplogroups in European 
populations were genotyped in 450 heart transplant recipients, 248 heart transplant 
donors, and 206 healthy controls. Mitochondrial haplogroups were determined by PCR 
amplification of short mtDNA fragments, followed by restriction fragment length 
polymorphism analysis. After adjustment for age and sex the frequency of haplogroup 
H was significantly higher in heart transplant recipients than in controls (OR 1.86 [95% 
CI 1.27-2.74], P=0.014), and in heart donors (OR 1.47 [95% CI 0.99-2.19], P=0.032). 
Likewise, haplogroup Uk was found significantly more frequently among CAV patients 
than in non-CAV heart allograft recipients (OR 4.1 [95% CI 1.51-11.42], P=0.042). 
Finally, heart donor haplogroups had no influence on the morbidity or mortality after 
heart transplantation. 
Conclusions Mitochondrial haplogroups behave like risk factors for the progress to 
end-stage HF in a Spanish cardiac transplant population. Mitochondrial DNA variants 
may have some influence on the appearance of cardiac transplant complications. 
 
Keywords heart failure, coronary allograft vasculopathy, heart transplantation; 
mitochondria; mitochondrial haplogroups 
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1. Introduction 
Heart failure (HF), the end-stage syndrome of many cardiovascular diseases, is a 
common, severe condition that places a great demand on health care resources. In 
Spain, several studies have reported a prevalence of HF of 6.8% in the Spanish 
population aged over 45 years and of 16% when only taking into account the population 
aged over 75 years.1,2 Because of its high incidence and poor prognosis, HF has been 
considered the genuine worldwide 21st century epidemic and new therapeutic 
approaches are encouraged to treat these patients.2 In this sense, cardiac transplantation 
is currently the only satisfactory long-term therapy available to treat refractory HF.1 
In spite of the advances in HF therapy over the last decade, HF remains a relentlessly 
progressive disease and the reason why heart failure progresses in patients receiving 
current optimal therapy remains unknown.2 There is increasing evidence that defective 
mitochondrial energetic and abnormal substrate metabolism are key characteristics of 
the failing heart,4 suggesting that benefit may be derived from therapies designed to 
preserve and optimize cardiac mitochondrial function.4 
Mitochondria are the site of pyruvate oxidation and the citric acid cycle, and they 
generate ATP by means of the electron transport chain and oxidative phosphorylation. 
Of the proteins directly needed for this activity, only 13 are encoded by the mtDNA 
itself, whereas about 80 proteins are coded by the nucleus and subsequently imported 
from the cytoplasm into the mitochondria.5 Human mitochondrial DNA is a 16,569 base 
pair double-stranded circular molecule containing 37 genes, and is transmitted by the 
mother so that it undergoes negligible intermolecular recombination.5 In addition, the 
evolutionary rate of mtDNA is reported to be much higher than that of nuclear DNA. 
Consequently, polymorphisms in mtDNA are expected to contribute more extensively 
to the functional differences among individuals than those in nuclear DNA.5 Among the 
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numerous mutations that have accumulated in mtDNA during evolution there are 
several ethnic specific single nucleotide polymorphisms that enable the definition of 
discrete and region specific subdivisions of the human population called mitochondrial 
haplogroups. Mitochondrial energetic function is influenced by functional mtDNA 
variants that alter mitochondrial coupling efficiency and allow individuals to adapt to 
different energetic environments.5 Besides, these genetic variants have controversially 
been described to be associated to the individual predisposition to a wide spectrum of 
metabolic and degenerative diseases, including ischemic cardiovascular disease, as well 
as to cancer and longevity.5-7 
The relationship between mtDNA haplogroups and the development and progression of 
HF is unknown. For that reason, the primary aim of this study was to analyze the 
influence of mtDNA haplogroups on the evolutive course to refractory HF. The results 
reported here clearly show that mitochondrial haplogroups are associated with the 
progress of end-stage HF. Our analyses, although preliminary, also suggest an influence 
of the mitochondrial genetic background on coronary allograft vasculopathy in a 
Spanish cohort of heart transplanted patients. 
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2. Methods 
2.1. Study Subjects 
This study was approved by the ethics committee of the Puerta de Hierro University 
Hospital and complies with the principles of the Declaration of Helsinki. 
The studied cohort comprised 450 unrelated patients (mean age, 49.5+13.1 years; range 
10-68; 355 men) undergoing heart transplantation at our institution between 1984 and 
2008, and 248 donors (mean age, 30.6+11.8; range 10-56; 185 men) from the same time 
period. All patients and donors were Caucasians. Underlying cardiac disease in the 
cohort was ischemic heart disease in 174 (38.7%) patients, idiopathic dilated 
cardiomyopathy in 148 (32.9%), other causes of dilated cardiomyopathy in 20 (4.4%), 
valvular disease in 38 (8.4%), restrictive cardiomyopathy in 19 (4.2%), hypertrophic 
cardiomyopathy in 20 (4.4%), congenital heart disease in 14 (3.1%), and others in 17 
(3.8%). All patients presented end-stage chronic HF and were in the New York Heart 
Association (NYHA) functional class III (41%) or IV (59%) at the time of cardiac 
transplantation. Pre-transplant, transplant, and post-transplant data were extracted from 
our centre´s prospective Heart Transplant database. Patients followed our centre´s 
standard post-transplant clinical follow-up program. Endomyocardial biopsy (EMB) 
and invasive coronariography were used for the diagnosis of rejection and cardiac 
allograft vasculopathy (CAV), respectively, according to the International Society of 
Lung and Heart Transplantation criteria.8 Our follow-up protocol includes 10 EMBs 
during the first post-transplant year and afterwards only when clinically indicated. CAV 
is systematically investigated per protocol at 5 and 10 years post-transplant and in the 
presence of symptoms or signs of cardiac dysfunction (even subtle ones, such as 
appearance of premature beats or repolarization abnormalities on EKG). Intravascular 
ultrasound (IVUS) was performed routinely at the time of coronary studies since 1994, 
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but did not influence medical management of heart transplant recipients, since changes 
were introduced only after diagnosis of significant CAV, defined by the presence of 
angiographic stenoses >50% in main coronary vessels. In the absence of recent 
coronariography and IVUS, sudden death was always attributed to CAV unless 
necropsy evidenced an alternative cause.  
Patients received triple immunosuppressive therapy with calcineurin inhibitors 
(Ciclosporine A in most patients), an anti-metabolite drug (azathioprine until 1999 and 
mycophenolate mofetil thereafter) and prednisone. Steroid withdrawal was attempted 
only in a minority of patients who developed severe side-effects. All of them received 
statins for CAV prevention irrespective of their lipid levels. No other drugs were used 
routinely. Treatment of hypertension was usually started with ACE inhibitors or 
angiotensin receptor blockers (ARB). 
 
2.2. Healthy controls 
The control group comprised 206 Caucasian blood donors from our institution (mean 
age, 37.7+11.5 years; range, 18-63; 110 men) who were receiving no pharmacologic 
treatment and showed no evidence of heart disease according to their medical history.  
 
2.3. Mitochondrial haplogroup genotyping 
Our study was designed and performed in accordance with the recommendations for the 
human genotype-phenotype associations.9 Genomic DNA was extracted from blood 
following standard procedures.10 The samples were haplogrouped by PCR amplification 
of short mtDNA fragments, followed by restriction fragment length polymorphism 
(RFLP) analysis to assess the mtDNA haplogroups, as previously described11 but with 
minor modifications (Table 1).12 Individuals with haplogroups L and M (pointing to 
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some non-Caucasian ancestry), with Caucasian haplogroups with low representation (I, 
W, X), or with haplogroups not ascribed to any of the known Caucasian haplogroups 
were grouped in haplogroup O. In individuals belonging to haplogroup H we also 
genotyped polymorphisms that corresponded to subhaplogroups H1 (m.3010G>A), H3 
(m.6776T>C) and H* (the rest of H subhaplogroups pooled together). To ensure proper 
internal control, for each genotype analysis, positive and negative controls from 
different mtDNA aliquots which were previously genotyped by the same method have 
been used. Besides, external control samples from standard accepted sets have been 
haplogrouped. For all the haplogroup markers, the RFLP analyses were carried out by 
two experienced researchers who were blind to subject data. Primers, PCR and RFLP 
conditions are available upon request. 
 
2.4. Statistical analysis  
Statistical analyses were performed using SPSS software for Windows version 14.0 
(Chicago, IL, USA). The number of patients and controls fulfilled sample size 
estimations based on Fleiss,13 which setting a statistical power of 80%, a significance 
level of 0.05, and a 2:1 patient-control ratio, indicated a minimum of 297 heart 
transplant recipients and 148 controls for detecting an OR of 1.8 for an association of 
end-stage heart failure with the most common haplogroup in Spanish Caucasoids 
(haplogroup H: 39% 6). Results were expressed as mean + standard deviation (SD) for 
numerical variables and as proportions for categorical variables. One-way analysis of 
variance (ANOVA) was used to assess the independence of the haplogroup distribution 
regarding age, body mass index (BMI), ischemia time, and left ventricular ejection 
fraction (LVEF). The differences in haplogroup frequency distribution between patients 
and controls were assessed by the χ2-independence test for the other cardiovascular risk 
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factors, such as hypertension and diabetes. Haplogroup frequencies in heart allograft 
recipients and donors were compared in the same way, but we compared each heart 
donor haplogroup with all other haplogroups pooled into a single group, as previously 
described7. The odds ratio (OR) and 95% confidence intervals (CI) were calculated to 
estimate the strength of association between the mitochondrial haplogroups and end-
stage HF. To adjust for demographic variables such as age and sex a multivariate 
logistic regression model has been used. Contingency tables and χ2 test were also used 
to predict possible interactions between clinical post-transplant variables and 
mitochondrial haplogroups. The Kaplan-Meier method and log-rank tests were used to 
compare the distributions of post-transplant survival according to the different 
haplogroups. A two-sided p value less than of 0.05 was considered statistically 
significant. The p-values of statistically significant differences were then corrected by 
the Bonferroni method (Corrected P-value= p-value*n [number of independent test]). 
The etiologic fraction (proportion of the genetic risk to a disease contributed by an 
analysed factor) was calculated by the formula: f(OR-1)/OR, where f is the frequency of 
the analysed factor in patients and OR, the odds ratio. 
 
3. Results 
3.1. Frequencies of mitochondrial haplogroups 
In order to evaluate the potential genetic association between the mitochondrial 
haplogroups and end-stage heart failure in patients undergoing cardiac transplantation, 
the frequency of nine European mitochondrial haplogroups in control (n=206), heart 
donor (n=248) and heart allograft recipient (n=450) populations was estimated. Because 
of the low frequencies of several mtDNA variants we grouped the patients in seven 
haplogroups according to their proposed evolutionary proximity.11 In this way, the 
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minimum expected frequency to ensure accuracy in the χ2-independence test is reached. 
The demographic characteristics of the study subjects are shown in Table 2. Different 
age and gender distribution was found among groups. These differences in some way 
were predictable because as it has been published, most of HT recipients are older age 
men and by contrary most of the donors are young men.1 A one-way analysis of 
variance and contingency tables analyses demonstrated no variations in the distribution 
of haplogroups in relation with age (p=0.32) and sex (p=0.55) of the heart recipients. 
On the one hand, the frequencies observed in the control group and in the heart donors 
were similar (Table 3), and consistent with previous studies of Spanish12,14 and 
European7,15 populations. Frequencies obtained ranged from 40.3% in the control 
population and 44% in heart donors for the most common haplogroup H (Table 3). On 
the other hand, the frequency of haplogroup H (OR=1.75, [95% CI 1.25-2.45] P=0.006, 
etiologic fraction=23.2%) was significantly higher in cardiac transplant recipients than 
in controls (Table 3). This haplogroup also remained significantly higher in heart 
transplant patients than in controls after correcting for age and gender (Table 3). In both 
groups the most prevalent H subhaplogroups in Western Europe (H1, H3) and H* were 
also genotyped (data not shown). The results did not show a statistical significance (OR 
0.93 [95% CI 0.76-1.13], p=0.42), and no H subhaplogroup has been significantly more 
frequent in patients than in controls. Besides, the frequency of haplogroups T and Uk 
was slightly but not significantly lower in heart allograft recipients than in controls 
(Table 3). This result might be attributed to the small number of patients carrying these 
haplogroups. To verify if this difference achieves statistical significance a larger cohort 
of patients would be necessary. 
Furthermore, we also performed a χ2-independence test dividing our patients 




predominant conditions leading to heart transplantation: ischemic heart disease and 
idiopathic dilated cardiomyopathy. As expected, the frequency of haplogroup H was 
higher in both subgroups of patients (OR 1.70 [95% CI 1.13-2.56], P=0.001 and OR 
1.56 [95% CI 1.02-2.39], P=0.03 respectively) than in controls (adjusted values for age 
and gender: (OR 1.86 [95% CI 1.02-3.41], P=0.044 and (OR 1.58 [95% CI 0.97-2.59], 
P=0.05 respectively). However, it was independent of the underlying cause of the end-
stage HF (OR 1.09 [95% CI 0.70-1.69], p=0.71) because it was similar in patients 
undergoing heart transplantation because of ischemic heart disease (53.4%) or dilated 
cardiomyopathy (51.4%) (Table 4). 
 
3.2. Pretransplant risk factors for heart failure and mtDNA haplogroups 
In order to elucidate if the high frequency of haplogroup H in the patients was 
associated with major risk factors for cardiovascular disease instead of the HF itself, we 
estimated the frequency of each haplogroup according to different pretransplant 
variables like body mass index (BMI), blood pressure, total cholesterol, and diabetes 
mellitus (Table 5a). No associations were found between mitochondrial haplogroups 
and risk factors for cardiovascular disease, indicating that the high frequency of 
haplogroup H is owed to the cardiac dysfunction itself. In addition, no associations were 
observed between HF severity, evaluated by LVEF and NYHA functional classes, and 
mitochondrial haplogroups (Table 5b). 
 
3.3. Role of mitochondrial haplogroups in the transplant and post-transplant 
follow-up 
To investigate the potential association between the mitochondrial genetic background 




Kaplan-Meier analyses were performed. No significant differences were observed 
between haplogroups and the preoperative ischemic time (212.4+62.3 min; range 70-
430), or post-transplant tumor development (Table 6). Likewise, Kaplan-Meier analysis 
showed no significant differences between the post-transplant median survival years 
and the haplogroup frequencies (median survival [95% CI], 11.96 years [10.19 to 13.73; 
overall log rank, p=0.82], even when we compared post-transplant median survival 
years between patients with haplogroup H (H survival) and patients with the rest of 
haplogroups pooled together (non-H survival) (Figure 1). Finally, the presence of 
coronary allograft vasculopathy (CAV), the major factor limiting long-term survival 
after heart transplantation, was evaluated only in 320 patients and was diagnosed in 111 
(34.7%) of them (Table 6). Interestingly, the frequency of haplogroup Uk (OR 4.1 [95% 
CI 1.49-11.24], P=0.021) was significantly higher in CAV than in non-CAV heart 
allograft recipients when each group was compared with all of the other haplogroups 
pooled together (Table 6). This association remained after adjusting for age and gender 
(Table 7). Besides, when we only compared the frequencies of haplogroup Uk and the 
most prevalent haplogroup H, a significantly higher frequency of haplogroup Uk in 
CAV heart allograft recipients was also observed (OR 3.93 [95% CI 1.40-11.00], P= 
0.049; adjusted values for age and sex (Table 7). 
 
3.4. Heart donor haplogroups and post-transplant follow-up  
The distribution of donor haplogroups in relation with age (p=0.55) and sex (p=0.64) of 
the heart donors was analyzed and, like in the heart recipient population, no variations 
were observed. Likewise, as it was expected, the frequency of haplogroup H (OR 1.51 




allograft recipients. Haplogroup H also remained significantly associated after 
correcting for age and gender (OR 1.47 [95% CI 0.99-2.19] P=0.032). 
To study the influence of the heart donor haplogroups on morbidity and mortality after 
heart transplantation, we were able to recover only 248 genetic samples of heart donors. 
Of these, only 141 were matched with the allograft recipient haplogroups. Due to the 
low frequencies of the haplogroups in the 141 heart recipient-donor pairs we pooled the 
heart recipients in two groups: group H-H (58 patients), when heart recipients and 
donors exhibited the same haplogroup H, and group H-non H (83 patients), when heart 
recipients presented haplogroup H and heart donors exhibited a different haplogroup.  
Regarding to the development of CAV in the heart allograft recipients, no significant 
differences were observed when we compared H-H and H-nonH groups (OR 1.09 [95% 
CI 0.48-2.46], p=0.82), suggesting that the presence of CAV in the allograft recipients 
was independent of heart donor haplogroups. Likewise, the influence of heart donor 
haplogroups on the overall post-transplant mortality was evaluated, and no significant 
differences (OR 1.57 [95% CI 0.79-3.13] p=0.19) were found between the H-H versus 
H-nonH groups. In summary, the results reported here suggest that heart donor 
haplogroups have no influence on morbidity or mortality after heart transplantation. 
 
4. Discussion 
The contribution of the genetic background to health and disease are research areas of 
paramount interest. At this moment, there are several studies that report that common 
mitochondrial DNA haplotypes, not only in humans but also in mice, are associated 
with various phenotypes including learning performance and the penetrance of some 
mtDNA-linked diseases.5,16 However, the involvement of mitochondrial haplogroups in 




clarify this issue have been carried out. For example, it was reported that the N9b 
haplogroup may be considered protective against myocardial infarction in Japanese 
men,16 that haplogroup T is associated with coronary artery disease in a middle 
European population,18 and recently haplogroup H was associated with early onset 
myocardial infarction in patients from the North of Spain.20 However, these results have 
not been reproduced and no association of mitochondrial haplogroups with risk of 
ischemic cardiovascular disease or acute coronary syndromes was observed in other 
European studies.20, 21 
In the present report, the genetic association between European mitochondrial 
haplogroups and end-stage HF was evaluated in 450 patients undergoing heart 
transplantation. The similarity of haplogroup distribution found among our control and 
heart donor groups to the distributions reported in different Spanish and European 
studies suggests that our control, heart donor and recipient populations are 
representative of the general population.1 
One of the most outstanding results that emerges from our study is the 
overrepresentation of mitochondrial haplogroup H in patients with refractory HF. This 
suggests that this haplogroup may have a role in heart energy metabolism, and thus 
contributes to HF progression. Until now, several articles have been published pointing 
out a biological role of this haplogroup under energetic and metabolic stress conditions. 
For instance, it has been reported that haplogroup H might be a predisposition factor for 
neurodegenerative diseases.7,5 It has also been associated with a better survival rate in 
patients with sepsis, and with protection against progression of the acquired immune 
deficiency syndrome (AIDS).5 Finally, a recent study by Palacin et al. supports an 
association of mitochondrial haplogroup H in a Spanish population with early onset of 




disease in our cohort includes not only patients with ischemic heart disease but also 
with other cardiomyopathies, both studies coincide in the association of haplogroup H 
with cardiac disease. 
The functional mechanism by which HF progression could be influenced by haplogroup 
H is still unknown. On the one hand, it has been reported that the capacity of the 
mitochondrial oxidative phosphorylation, when HF is established, is reduced and linked 
to a progressive mechanical dysfunction of cardiomyocyte sarcomeric proteins.4 In this 
sense, the higher frequency of haplogroup H found in patients with end-stage HF might 
be indicating a less efficient mitochondrial ATP production than in other haplogroups, 
and consequently a greater mechanical failure of the hearts of these patients. On the 
other hand, it has been observed that the activity of the electron transport chain (ETC) 
enzymes was normal in the ventricular myocardium of an animal HF model, and that 
the defect mainly resides in the assembly and function of a major ETC supercomplex 
(respirasome).22 In that way, haplogroup H may influence not only ATP and reactive 
oxygen species (ROS) production, but also ETC assembly kinetics when the respiratory 
demand increases in the heart, and this could be an additional contributing factor to the 
pathogenetic mechanism involved in end-stage HF. In fact, different assembly rates of 
respiratory chain supercomplexes belonging to different mitochondrial haplogroups 
have been shown to occur in a cellular model of mitochondrial disease.23 However, 
further functional studies on a cardiomyocyte model are needed to elucidate this and 
other issues of the physiopathologic mechanisms of end-stage HF. Finally, a reduced 
mtDNA replication and a downregulation of the mitochondrial transcription cascade 
have recently been observed in human and experimental failing hearts.24 This fact, 
combined with the decreased mtDNA copy number that has been observed in vitro in 




haplogroup H under conditions of increased energy demand (like in cardiac 
dysfunction), thus exacerbating the constant progress of the HF.25 
Recently, it was suggested that mitochondrial haplogroups play a role in several risk 
factors for cardiovascular diseases such as hypertension, obesity, hyperlipemia, and 
metabolic syndrome.5 However, the lack of association between mitochondrial 
haplogroups and pretransplant risk factors for heart failure in our study is in accordance 
with other results found in European populations.20 These risk factors are influenced by 
multi-genetic and environmental conditions, and conflicting results might reflect a 
modest role of mitochondrial haplogroups in the pathogenetic mechanisms of these late-
onset diseases. In the same manner, we were unable to detect any association of 
mitochondrial haplogroups with the severity of HF, as indicated by LVEF and NYHA 
functional classes. However, a limitation of this study is the lack of patients in earlier 
stages of heart failure, long before undergoing cardiac transplantation. For that reason, 
to understand the involvement of mtDNA variants in the progress of failing heart, 
patients at early stages of HF need to be studied.  
Additionally, although preliminar, this is the first study showing that mtDNA 
haplogroup Uk may be associated with an increased risk of CAV, a model of chronic 
rejection involving the entire length of the transplanted vessels.8,26 It is believed that 
CAV is caused by immunologic mechanisms and non-immunologic factors, including 
free radical-induced damage.26 Mitochondrial haplogroup Uk, a subgroup of haplogroup 
U, has been considered as protective against developing idiopathic Parkinson´s disease,7 
AIDS progression, and to be associated with increased serum immunoglobulin E level.5 
Although the mechanisms underlying these associations remain unclear, haplogroup-
specific differences in immunologic pathways and ROS generation in mitochondria 




proinflammatory cytokines are influenced by different genetic polymorphisms, and 
some of them are predictors of cardiovascular disease.27 Haplogroup Uk might be 
related with a higher expression of cytokines and immune response than other 
mitochondrial haplogroups, and for that reason it could be overrepresented in allograft 
recipients with CAV. A further replication of this study in a higher number of cardiac 
allograft recipients with CAV is neccesary to assess the reproducibility of these 
findings. 
Finally, the influence of heart donor haplogroups on the morbidity or mortality 
observed after heart transplantation has been analysed. As we expected, the haplogroup 
distribution among heart donors was similar to that observed in our control population. 
For the same reason, the frequency of haplogroup H was lower in heart donors than in 
cardiac allograft recipients. However, the post-transplant course of the cardiac allograft 
recipients was independent of heart donor haplogroups, without any influence of 
mitochondrial haplogroups of the donors on CAV or mortality. Although an association 
between the recipient haplogroups with longevity has been found in several European 
and Asiatic studies,5 we and others20 were unable to reproduce this association. This fact 
probably reflects the differences in the approach and design of the analyses. 
In summary, the results reported here show mitochondrial haplogroups as risk factors 
for the progression of end-stage HF, and possibly for allograft complications in a 
Spanish cardiac transplant population. These results may provide a reliable starting 
point for further investigations on the relationships between end-stage HF, 
mitochondrial genetic background, and the pathological mechanisms that could 
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Figure 1.- Cumulative survival of cardiac allograft recipients as a function of post-
transplant years: 1A. In the overall allograft recipient population; 1B. Comparison of 
the post-transplant survival years between patients with haplogroup H (H survival) and 
patients with the rest of haplogroups pooled together (non-H survival). 
